NSPR Q1 2026 Earnings Call Summary

Summary of InspireMD's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Revenue: $3.4 million for Q1 2026, a 122% increase from $1.5 million in Q1 2025.
U.S. Revenue: $1.2 million, representing 36% sequential growth from Q4 2025.
International Revenue: $2.2 million, up 48% year-over-year, aided by an 11% contribution from favorable foreign exchange rates.
Gross Profit: $0.7 million (20.2% of revenue), improved from $0.3 million (19.1% of revenue) in Q1 2025. Adjusted gross profit (excluding impairment) was $1.2 million (34.1% of revenue).
Net Loss: $13.7 million ($0.16 per share), widening from a net loss of $11.2 million ($0.22 per share) in Q1 2025.
Cash Position: $41.6 million as of March 31, 2026, down from $54.2 million at the end of 2025.

2. Strategic Updates and Business Highlights

CGuard Implant Demand: Strong global demand for the CGuard implant, attributed to its clinical profile and physician interest.
Commercialization Pause: A voluntary pause in the U.S. commercialization of the CGuard Prime 135 delivery system due to technical performance issues, not related to safety.
FDA Engagement: Positive discussions with the FDA regarding the approval of the original CGuard delivery system, expected in Q3 2026.
Clinical Trials: Initiation of the C-GUARDIANS III clinical trial for the next-generation SwitchGuard neuroprotection system is underway.

3. Forward Guidance and Outlook

Revenue Guidance: Full-year 2026 revenue guidance has been withdrawn due to uncertainties surrounding the U.S. market re-entry and the CGuard Prime system.
Market Potential: Anticipated FDA approval of the CGuard Prime 80 system for TCAR procedures could potentially double the U.S. addressable market.
Long-Term Confidence: Management remains optimistic about the long-term growth trajectory, citing strong international performance and physician confidence.

4. Bad News, Challenges, or Points of Concern

U.S. Commercialization Setback: The pause in the U.S. market for the CGuard Prime delivery system represents a significant challenge to commercial momentum.
Impairment Charges: A $473,000 impairment charge related to excess inventory.
Operating Expenses: Increased operating expenses ($14.7 million), driven by staffing and marketing for the U.S. launch, which may continue to rise as R&D investments are made.
Cash Burn: The company is experiencing a significant net loss, raising concerns about cash management during the commercialization pause.

5. Notable Q&A Insights

Regulatory Process: Management is confident in resolving technical challenges with the CGuard Prime delivery system and is working towards resubmission to the FDA, with hopes for early 2027 approval.
Customer Engagement: Existing customers are expected to be receptive to the original CGuard system upon re-entry, with ongoing engagement despite the pause.
Operational Stability: While operational expenses are expected to remain stable, there may be a pause in headcount investments until there is more clarity on FDA timelines.
Market Awareness: Despite the pause, there is strong market awareness and demand for the CGuard implant, which may facilitate a quicker recovery once products are reintroduced.

This summary encapsulates the key points from InspireMD's Q1 2026 earnings call, highlighting both the positive aspects of their financial performance and strategic initiatives, as well as the challenges they face moving forward.

NSPR — InspireMD, Inc.